APIs, Excipients, and Manufacturing eBook
Read the article:
Seeking Economies of Scale for Biocatalysis
Read the ebook:
Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook
New enzymes and protein engineering have advanced biocatalysis processing toward commercial acceptance. Technology and economic roadblocks must be overcome for the process to be widely embraced by pharma.
The advantages that enzymes have as biocatalysts are well known within the pharmaceutical manufacturing industry, not least that they can give excellent specificity and yields, and even facilitate reactions that are difficult with chemical catalysts. Their credentials towards improving sustainability are also increasing the levels of interest for process development, as biocatalytic reactions can be more efficient in terms of solvent and material use.
Read this article in Pharmaceutical Technology’s October 2021 APIs, Excipients, and Manufacturing eBook.
Read the article:
Seeking Economies of Scale for Biocatalysis
Read the ebook:
Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook
Mark Muldowney is head of technology, and innovation and Greg Holgate is biocatalysis chemist, both with Sterling Pharma Solutions.
Pharmaceutical Technology
eBook: APIs, Excipients, and Manufacturing
October 2021
Pages: 12–16
When referring to this article, please cite it as M. Muldowney and G. Holgate, “Seeking Economies of Scale for Biocatalysis,” Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook (October 2021).
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.